Novartis may have signed off on the second-largest pharma acquisition of 2025 so far, but as the company’s CEO sees it—it’s never about the price tag. | Novartis may have signed off on the second ...

After laying off 80% of staffers this spring, Tempest Therapeutics is acquiring several CAR-T programs from Factor Bioscience ...

As the biopharma world predominantly zeroes in on late-stage assets, Eli Lilly is prioritizing early science with the opening ...

Lumexa Imaging, formerly known as US Radiology Specialists, has filed with the SEC to go public and is set to raise as much ...

“Under Belgian rules, you can't really do that because it takes a 75% vote,” Gosebruch explained. “Gilead owns 25% and ...

Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval ...

Korea’s Celltrion is continuing to think bigger than biosmilars, this time securing the option to use TriOar’s antibody ...

Precise Bio has reported the first successful human implantation of its 3D-printed cornea implant, constructed of functional ...

Dexcom has obtained an FDA clearance for its basal insulin dosing optimizing program, designed for adults with Type 2 diabetes using its continuous glucose monitors.  | Dexcom said Smart Basal is the ...

Johnson & Johnson is paying $3.05 billion to acquire Halda Therapeutics, obtaining a novel cell death platform while ...

GSK has paid $50 million upfront to partner with LTZ Therapeutics on myeloid cell engagers, expanding its cancer pipeline to cover a modality that has attracted Eli Lilly, Novartis, Pfizer and Sanofi.

Cytokinetics may be counting down the days until the FDA decides whether to approve its cardiovascular drug aficamten. | ...